Breathtaking science
Developing innovative therapeutics to transform
the standard of care for respiratory diseases
20 February 2019
Verona Pharma to Announce Financial Results for Full Year ended December 31, 2018 and Provide Clinical Development Update
LONDON, Feb. 20, 2…
4 February 2019
Verona Pharma to Present at Upcoming Investor Conferences
LONDON, Feb. 04, 2019 (GLOBE NEWSWIRE) -- Verona Pharma plc (AIM: VRP) (NASDAQ: V…
Unique mechanism of action
Our breakthrough lead product, ensifentrine (RPL554), is first-in-class. It offers a unique, dual mechanism of action unlike any other type of drug currently available or in development for respiratory diseases
53.50p
0.00 (0.00%)
LON: VRP
5.80USD
-0.18 (-3.01%)
NASDAQ: VRNA
Verona Pharma plc
3 More London Riverside
London SE1 2RE
United Kingdom
E: info@veronapharma.com
T: +44 (0)203 283 4200
Registered address
One Central Square
Cardiff CF10 1FS
United Kingdom
US Investor relations contact
ICR, Inc.
E: ICR_Verona@icrinc.com
T: +1 646-277-1282
UK Investor relations contact
FTI Consulting
E: veronapharma@fticonsulting.com
T: +44 (0)20 3727 1000
Nominated adviser and broker
Stifel Nicolaus Europe Limited
150 Cheapside
London EC2V 6ET
United Kingdom
T: +44 (0)207 710 7600